Short answer
Schrodinger, Inc. (SDGR) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $54M (up 53.9% year over year) with net income of −$33M.
Q3 2025 key financials · XBRL
- Revenue
- $54M
- +53.9% YoY · −0.8% QoQ
- Net income
- −$33M
- +14.0% YoY · +24.0% QoQ
- Operating margin
- -84.6%
- Gross margin
- 51.6%
- EPS (diluted)
- −$0.44
- +15.4% YoY · +25.4% QoQ
Source: XBRL data from the Schrodinger, Inc. (SDGR) Q3 2025 10-Q on SEC EDGAR. USD.
Schrodinger, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $54.3M, up 54% YoY from $35.3M
- Net loss $32.8M vs $38.1M YoY
- Restructuring reducing annualized operating expenses approximately $30M
- Workforce reduced approximately 60 employees, representing approximately 7% of full-time employees
- Cash savings approximately $70M expected from phasing out independent clinical development and restructuring
Risk Factors
- Operating losses: net loss $135.8 million for nine months ended September 30, 2025, with accumulated deficit of $661.3 million
- Liquidity: $401.0 million in cash, restricted cash, and marketable securities expected to fund operations through at least 24 months
- Revenue concentration: software renewals and sales to biopharmaceutical customers remain critical to operating results
- Competitive pressure: competitors include established providers and machine-learning drug-discovery companies with greater resources
- Accounting compliance: changing financial-reporting standards could require policy changes, system enhancements, or financial-statement restatements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Schrodinger, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.